Cargando…

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan

BACKGROUND: Cabazitaxel is an efficacious treatment for patients with metastatic castration-resistant prostate cancer who have previously progressed on docetaxel, but febrile neutropenia during the first cycle is a frequent complication. Asian patients are at increased risk of febrile neutropenia. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosaka, Takeo, Uemura, Hiroji, Sumitomo, Makoto, Harada, Kenichi, Sugimoto, Mikio, Hayashi, Narihiko, Yoshimura, Kazuhiro, Fukasawa, Satoshi, Ecstein-Fraisse, Evelyne, Sunaga, Yoshinori, Oya, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939836/ https://www.ncbi.nlm.nih.gov/pubmed/31329922 http://dx.doi.org/10.1093/jjco/hyz051

Ejemplares similares

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
por: Watanabe, Keitaro, et al.
Publicado: (2021)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2017)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report
por: Kosaka, Takeo, et al.
Publicado: (2019)

Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel
por: Kosaka, Takeo, et al.
Publicado: (2018)

Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry
por: Malik, Zafar, et al.
Publicado: (2020)

Real-world experience with cabazitaxel in patients with metastatic castration-resistant prostate cancer: a final, pooled analysis of the compassionate use programme and early access programme
por: Malik, Zafar, et al.
Publicado: (2019)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Influence of response to prior docetaxel on sensitivity to cabazitaxel in prostate cancer patients with PTEN alterations
por: Kamisawa, Ken, et al.
Publicado: (2022)

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Uemura, Koichi, et al.
Publicado: (2018)

A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer
por: Akaza, Hideyuki, et al.
Publicado: (2016)

Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy
por: Uemura, Koichi, et al.
Publicado: (2017)

The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study
por: Uemura, Hiroji, et al.
Publicado: (2022)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Yasumizu, Yota, et al.
Publicado: (2021)

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity
por: Kosaka, Takeo, et al.
Publicado: (2013)

Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan
por: Matsuyama, Hideyasu, et al.
Publicado: (2023)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
por: Yamamoto, Teppei, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
por: Colbourn, Donald
Publicado: (2012)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
por: Patel, Sheel A, et al.
Publicado: (2017)

Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020)

Prognostic value of automated bone scan index for predicting overall survival among bone metastatic castration resistant prostate cancer patients treated with radium‐223
por: Miyoshi, Yasuhide, et al.
Publicado: (2020)

Risk Factors for Metastatic Castration-Resistant Prostate Cancer (CRPC) Predict Long-Term Treatment with Docetaxel
por: Kawahara, Takashi, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6et7hndl22dpvqt1hmeld7ufh2